Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial
Authors' conclusion
PTF reduced SA progression assessed by CIMT variation, a beneficial effect related to KL gene expression in PBCs.
Study context
- Population
- Patients with T2D and moderate to severe chronic kidney disease (CKD)
- Participants
- 102 patients
- Comparison
- Pentoxifylline (PTF) vs aspirin vs control
- Primary endpoint
- Progression of subclinical atherosclerosis: evolution of carotid intima-media thickness (CIMT) and ankle-brachial index (ABI)
- Follow-up
- 18 months
Methodological detailsopen-label, prospective, single-centre, pilot
- Open-label
- Prospective
- Single-centre
- Pilot
Primary result
As reported in the abstract
CIMT progression
PTF treatment, changes in Klotho (KL) mRNA in peripheral blood cells (PBCs) and HDL changes were significant determinants of carotid intima-media thickness (CIMT) progression, independent of traditional risk factors (multiple regression)
adjusted R2 = 0.24
P < 0.001
PTF treatment as protective factor against worst CIMT progression
OR: 0.103
P = 0.001
Variation in KL mRNA in PBCs as protective factor against worst CIMT progression
OR 0.001
P = 0.005
Further findings
Klotho (KL) and inflammatory markers
- PTF increased KL mRNA levels in peripheral blood cells (PBCs) and reduced the inflammatory state
- CIMT progression inversely related to KL variations in serum and PBC mRNA
Original publication
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial. Cardiovasc Diabetol. Published 24 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →